Northwire Canada EditionTuesday, August 25, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0% GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0%
Financings Routine +

Alzai Health Corp. Files Final Prospectus in Connection With Initial Public Offering

Alzai Health Files Final Prospectus for $4M Best-Efforts IPO

By The Northwire Desk — AI Analysis Apr 22, 2026 · 16:17 ALZI
Executive Summary
  • Alzai Health Corp. has filed a final long-form prospectus to launch an Initial Public Offering (IPO) on the TSXV.
  • The offering consists of up to 10,000,000 units priced at $0.40 per unit.
  • Gross proceeds are targeted between $3,200,000 and $4,000,000.
  • Net proceeds will be allocated to research and development, sales and marketing, and general working capital.
  • Each unit includes one common share and one-half of a common share purchase warrant.
  • Warrants have an exercise price of $0.60 and expire 24 months from the closing date.
  • Haywood Securities Inc. is acting as the exclusive agent on a best-efforts basis with a 7% commission.
  • Closing and trading commencement are expected around May 21, 2026.
Material Impact
  • The filing represents a standard procedural milestone for an IPO rather than a fundamental business breakthrough.
  • Proceeds of $3.2M to $4.0M are modest for a healthcare company, suggesting limited runway without further financing.
  • Best-efforts structure indicates potential lack of strong institutional demand, which is a risk factor compared to firm-commitment underwritings.
  • The offering price ($0.40) sets the initial market valuation baseline; any premium depends on post-listing performance.
  • Warrant terms (50% upside trigger at $0.60) create potential dilution pressure if the stock rallies significantly within 24 months.
  • No strategic investors or anchor commitments are disclosed in this release, reducing confidence in immediate liquidity support.
ALZI · Price
Company Overview
  • Company Name: Alzai Health Corp.
  • Sector: Healthcare / Biotechnology (specific therapeutic focus not detailed in this prospectus summary).
  • Development Stage: Pre-revenue, seeking capital for R&D and commercialization.
  • Flagship Project: Details regarding specific assets or therapies are not explicitly outlined in the provided news text; investors must refer to the full prospectus for pipeline specifics.
  • Management Background: Not disclosed in this release; due diligence required on executive track record from full filing.
Read the original news release →

More from

Jun 09, 2026 · 08:23

Early-stage AI diagnostics IPO raises $4M to fund Alzheimer's screening R&D and commercialization.

Financings Jun 05, 2026 · 16:15

AI-driven Alzheimer's screening startup prepares for TSXV debut

Financings